Plasmodium vivax is an important cause of malaria, associated with a significant public
health burden. Whilst enhanced malaria-control activities have successfully reduced the …

Plasmodium vivax is the most geographically widespread human malaria parasite. Global
malaria efforts have been less successful at reducing the burden of P. vivax compared to P …

The deployment of artesunate for severe malaria and the artemisinin combination therapies
(ACTs) for uncomplicated malaria has been a major advance in antimalarial therapeutics …

Restrictions on the cultivation and ingestion of fava beans were first reported as early as the
fifth century BC. Not until the late 19th century were clinical descriptions of fava-induced …

Plasmodium vivax malaria continues to cause a significant burden of disease in the Asia-
Pacific, the Horn of Africa, and the Americas. In addition to schizontocidal treatment, the 8 …

Objective Risk of bias assessments are important in meta-analyses of both aggregate and
individual participant data (IPD). There is limited evidence on whether and how risk of bias …

Background The introduction of novel short course treatment regimens for the radical cure of
Plasmodium vivax requires reliable point-of-care diagnosis that can identify glucose-6 …

Background In 2017, an estimated 14 million cases of Plasmodium vivax malaria were
reported from Asia, Central and South America, and the Horn of Africa. The clinical burden of …

Abstract Glucose-6-phospate dehydrogenase (G6PD) deficiency is estimated to affect more
than 400 million people world-wide. This X-linked genetic deficiency puts stress on red …

Background Point-of-care glucose-6-phosphate dehydrogenase (G6PD) testing has the
potential to make the use of radical treatment for vivax malaria safer and more effective …